Immunome (IMNM) Receivables - Net (2021 - 2022)

Immunome's (IMNM) quarterly Receivables - Net came in at $17.4 million in Q2 2022, up 8600.0% on a QoQ basis from $200000.0 in Q1 2022.

Immunome (IMNM) Receivables - Net (2021 - 2022) Analysis & Trends

Immunome (IMNM) has 2 years of Receivables - Net data on file, last reported at $17.4 million in Q2 2022.

Quarterly Receivables - Net changed N/A year-over-year to $17.4 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $17.4 million (changed N/A YoY) and the FY2021 annual result came in at $200000.0, changed N/A from the prior year.
Receivables - Net improved to $17.4 million in Q2 2022, from $200000.0 in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $17.4 million in Q2 2022 to a low of $200000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Immunome	3.09 Bn	2.57 Bn	-

Download Data